CA2511385A1 - Non-hygroscopic formulation comprising a hydroscopic drug - Google Patents

Non-hygroscopic formulation comprising a hydroscopic drug Download PDF

Info

Publication number
CA2511385A1
CA2511385A1 CA002511385A CA2511385A CA2511385A1 CA 2511385 A1 CA2511385 A1 CA 2511385A1 CA 002511385 A CA002511385 A CA 002511385A CA 2511385 A CA2511385 A CA 2511385A CA 2511385 A1 CA2511385 A1 CA 2511385A1
Authority
CA
Canada
Prior art keywords
composition
hygroscopic
recited
drug
deliquescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511385A
Other languages
English (en)
French (fr)
Inventor
Ann M. Czyzewski
Danchen Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2511385A1 publication Critical patent/CA2511385A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
CA002511385A 2002-12-19 2003-12-05 Non-hygroscopic formulation comprising a hydroscopic drug Abandoned CA2511385A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43502202P 2002-12-19 2002-12-19
US43542202P 2002-12-19 2002-12-19
US43514702P 2002-12-19 2002-12-19
US60/435,147 2002-12-19
US60/435,422 2002-12-19
US60/435,022 2002-12-19
PCT/US2003/038792 WO2004060352A1 (en) 2002-12-19 2003-12-05 Non-hygroscopic formulation comprising a hydroscopic drug

Publications (1)

Publication Number Publication Date
CA2511385A1 true CA2511385A1 (en) 2004-07-22

Family

ID=32719157

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002511385A Abandoned CA2511385A1 (en) 2002-12-19 2003-12-05 Non-hygroscopic formulation comprising a hydroscopic drug
CA002509261A Abandoned CA2509261A1 (en) 2002-12-19 2003-12-11 Solid dispersions comprising a hygroscopic and/or deliquescent drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002509261A Abandoned CA2509261A1 (en) 2002-12-19 2003-12-11 Solid dispersions comprising a hygroscopic and/or deliquescent drug

Country Status (17)

Country Link
US (2) US20040197411A1 (enExample)
EP (2) EP1575563B1 (enExample)
JP (2) JP2006513238A (enExample)
AR (2) AR042511A1 (enExample)
AT (1) ATE353633T1 (enExample)
AU (2) AU2003298010A1 (enExample)
BR (2) BR0317392A (enExample)
CA (2) CA2511385A1 (enExample)
DE (1) DE60311875T2 (enExample)
ES (1) ES2280835T3 (enExample)
HN (1) HN2003000417A (enExample)
MX (2) MXPA05006802A (enExample)
NL (1) NL1025069C2 (enExample)
PE (1) PE20040972A1 (enExample)
TW (2) TW200423971A (enExample)
UY (1) UY28138A1 (enExample)
WO (2) WO2004060352A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
JP2006513238A (ja) * 2002-12-19 2006-04-20 ファルマシア・コーポレーション 吸湿性薬物を含む非‐吸湿性製剤
ATE359075T1 (de) * 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
JP2007532607A (ja) 2004-04-16 2007-11-15 シュバルツ　ファルマ　アクチェンゲゼルシャフト 慢性頭痛の予防及び治療のためのペプチド化合物の使用
EP1765309B1 (en) * 2004-07-02 2009-08-05 Radi Medical Biodegradable AB Smokeless toabacco product
ATE471717T1 (de) * 2004-08-27 2010-07-15 Ucb Pharma Gmbh Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20090304786A1 (en) * 2005-11-25 2009-12-10 Viswaprasad Varanasi Stable Dosage Forms of an Antidepressant
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
RU2406502C2 (ru) * 2006-06-06 2010-12-20 Тиботек Фармасьютикалз Лтд. Способ получения препаратов тмс125, полученных сушкой распылением
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2673536A1 (en) * 2006-12-22 2008-07-03 Yuhan Corporation Revaprazan-containing solid dispersion and process for the preparation thereof
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
CA2701388C (en) * 2007-08-30 2015-06-23 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
KR101499533B1 (ko) * 2008-02-15 2015-03-09 주식회사 씨티씨바이오 콜린 알포세레이트 함유 약학 제제
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101172699B1 (ko) 2011-05-16 2012-08-09 한국프라임제약주식회사 콜린알포세레이트를 함유하는 약학 제제, 및 그의 제조방법
JP2014522893A (ja) 2011-07-07 2014-09-08 ザ ルブリゾル コーポレイション ２ストロークサイクルエンジンのための改善された清浄性を提供する潤滑剤
CN102525992A (zh) * 2012-03-09 2012-07-04 徐奎 L-α-甘油磷酸胆碱薄膜衣片及其制备方法
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
WO2013175505A1 (en) * 2012-05-21 2013-11-28 Hetero Research Foundation Elvitegravir solid dispersion
HRP20251029T1 (hr) 2013-07-19 2025-10-24 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
PL3106150T3 (pl) * 2013-12-04 2022-01-03 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
GB2525170A (en) * 2014-04-07 2015-10-21 Nokia Technologies Oy Stereo viewing
CN104739776A (zh) * 2015-04-15 2015-07-01 福州乾正药业有限公司 左卡尼汀的固体分散体组合物及其制备方法和药物应用
WO2017013591A1 (en) * 2015-07-22 2017-01-26 Leiutis Pharmaceuticals Pvt Ltd Stabilized liquid formulation of levothyroxine
BR112018068986B1 (pt) * 2016-03-18 2023-03-21 Christopher Brian Reid Composição para reduzir a expressão oncógena de uma célula, tecido ou órgão de um indivíduo
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
JP7319247B2 (ja) * 2018-03-30 2023-08-01 株式会社カネカ 酸化型グルタチオンを含む固体組成物及びその製造方法
CN112316678A (zh) * 2020-10-12 2021-02-05 常州市永勃机械有限公司 一种变电站柜体用驱潮剂制备工艺制备方法
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835187A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
JPH02218621A (ja) * 1989-02-20 1990-08-31 Nippon Chemiphar Co Ltd 徐放性製剤
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US5688510A (en) * 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
JPH10182448A (ja) * 1996-12-24 1998-07-07 Zensei Yakuhin Kogyo Kk 圧縮製剤用組成物の製造方法
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
ZA200206459B (en) * 2000-03-24 2003-08-13 Pharmacia Corp Amidino compound and salts thereof useful as nitric oxide synthase inhibitors.
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
JP2006513238A (ja) * 2002-12-19 2006-04-20 ファルマシア・コーポレーション 吸湿性薬物を含む非‐吸湿性製剤

Also Published As

Publication number Publication date
WO2004060353A1 (en) 2004-07-22
AR042511A1 (es) 2005-06-22
EP1575564A1 (en) 2005-09-21
NL1025069C2 (nl) 2005-02-16
HN2003000417A (es) 2005-11-01
US20050013856A1 (en) 2005-01-20
JP2006513238A (ja) 2006-04-20
TW200423971A (en) 2004-11-16
UY28138A1 (es) 2004-08-31
AR042536A1 (es) 2005-06-22
ES2280835T3 (es) 2007-09-16
MXPA05005667A (es) 2005-07-26
US20040197411A1 (en) 2004-10-07
EP1575563A1 (en) 2005-09-21
WO2004060352A1 (en) 2004-07-22
DE60311875D1 (de) 2007-03-29
WO2004060352A8 (en) 2005-09-15
PE20040972A1 (es) 2004-12-14
AU2003296948A1 (en) 2004-07-29
CA2509261A1 (en) 2004-07-22
BR0317103A (pt) 2005-10-25
EP1575563B1 (en) 2007-02-14
NL1025069A1 (nl) 2004-07-01
BR0317392A (pt) 2005-12-20
ATE353633T1 (de) 2007-03-15
MXPA05006802A (es) 2005-09-08
TW200413006A (en) 2004-08-01
WO2004060353A9 (en) 2004-10-07
JP2006514052A (ja) 2006-04-27
AU2003298010A1 (en) 2004-07-29
DE60311875T2 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
US20040197411A1 (en) Acceptably non-hygroscopic formulation intermediate comprising a hygroscopic drug
KR102464646B1 (ko) (r)-2-아미노-3-페닐프로필 카바메이트의 제제
AU2008213744B2 (en) A dosage form containing two or more active pharmaceutical ingredients in different physical forms
US6033686A (en) Controlled release tablet of bupropion hydrochloride
US8501227B2 (en) Stable pharmaceutical compositions without a stabilizer
KR20100103824A (ko) 약학적 조성물
EA024699B1 (ru) Фармацевтическая таблетка с немедленным высвобождением, содержащая севеламера карбонат
US10350194B2 (en) Pharmaceutical composition containing an arylalkylamine compound
KR20230056789A (ko) 다파글리플로진 공결정의 약학 조성물
JP2025013661A (ja) レボカルニチン含有錠剤
CA2067733C (en) Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure
JP2016050206A (ja) レボカルニチンを含有する医薬錠剤
JP5718937B2 (ja) パーキンソン病を治療するための医薬組成物及びその調製方法
WO2013106526A1 (en) Saxagliptin parmaceutical formulations
WO2015022559A1 (en) Pharmaceutical composition containing rosuvastatin and ramipril
WO2020003196A1 (en) Pharmaceutical composition of axitinib
JP2017525731A (ja) ドキシラミン並びにピリドキシン及び／またはそれらの代謝産物もしくは塩の多峰性放出製剤
RU2188019C1 (ru) Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения
US20070231390A1 (en) Formulations including hygroscopic compounds
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
WO2014007065A1 (ja) 固形医薬錠剤およびその製造方法
AU2013202526A1 (en) A dosage form containing two or more active pharmaceutical ingredients in different physical forms

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued